Nanoparticle-Proton combo for recurrent cancer trial pulled before start
NCT ID NCT04784221
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study aimed to test whether combining special nanoparticles with proton radiation could help control cancers that return after previous radiation treatment. The trial was planned for adults with tumors in specific areas like the skull base or throat. However, the study was withdrawn before any patients were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AGuIX® nanoparticles
What this could lead to
If successful, this approach could offer a new way to treat cancers that return after previous radiation therapy.
What could go wrong
This trial was withdrawn before enrolling any participants, so no results are available. The combination is experimental and may not prove effective or safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.